Mineralys Therapeutics, Inc. Common Stock
MLYS
$28.43
+9.22%
Mineralys Therapeutics is a biopharmaceutical company focused on developing treatments for diseases driven by dysregulated aldosterone. It is a clinical-stage biotech with a core narrative centered on its lead candidate, lorundrostat, a selective aldosterone synthase inhibitor for cardiorenal conditions.…
MLYS
Mineralys Therapeutics, Inc. Common Stock
$28.43
Investment Opinion: Should I buy MLYS Today?
Based on a synthesis of the data, the objective assessment is a Speculative Buy for Risk-Tolerant Investors. The uniform positive sentiment from available analyst coverage, strong balance sheet, and large addressable market for its lead drug candidate provide a compelling narrative. However, this rating is heavily qualified by the extreme binary risk inherent in clinical-stage biotechs, the lack of current revenue, and the stock's recent bearish technical performance. It is not suitable for conservative or income-seeking investors.
Sign up to view all
MLYS 12-Month Price Forecast
The investment thesis is entirely event-driven. The strong financial base provides a margin of safety for the clinical gamble, but the recent price action and high short interest reflect deep market skepticism. The neutral stance balances the promising fundamentals against the extreme volatility and lack of near-term catalysts.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mineralys Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $36.96 and implied upside of +30.0% versus the current price.
Average Target
$36.96
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$23 - $37
Analyst target range
Wall Street analyst coverage for MLYS is limited but uniformly positive among the firms providing recent ratings. The most recent actions from B of A Securities, Stifel, HC Wainwright & Co., and Wells Fargo all maintain 'Buy' or 'Overweight' ratings. However, specific consensus target prices, ratings distribution percentages, and the number of analysts covering the stock are not provided in the data. Therefore, while the available sentiment is bullish, no sufficient analyst coverage data is available to form a detailed quantitative consensus.
Bulls vs Bears: MLYS Investment Factors
MLYS is a high-risk, high-reward clinical-stage biotech. Its value is entirely tied to the success of its lead drug candidate, lorundrostat, supported by a strong balance sheet but challenged by a lack of revenue and a declining stock price.
Bullish
- Positive Analyst Sentiment: Recent analyst actions from major firms maintain 'Buy' or 'Overweight' ratings.
- Strong Financial Position: Zero debt and a high current ratio of 43.76 provide ample liquidity.
- High Market Potential: Lead candidate lorundrostat targets large cardiorenal disease markets.
- Improving Loss Profile: Q4 2025 net loss of $32.2M improved from $48.9M in Q4 2024.
Bearish
- Pre-Revenue, No Earnings: Zero revenue, negative EPS, and no traditional valuation metrics apply.
- High Cash Burn: Negative free cash flow of -$37.9M last quarter funds R&D.
- Bearish Price Trend: Down 33% over six months, underperforming the S&P 500 significantly.
- High Short Interest: Short ratio of 7.77 indicates significant market skepticism.
MLYS Technical Analysis
The stock's overall trend has been bearish over the last six months, with the price declining from approximately $40.46 in early October 2025 to $27.09 as of March 31, 2026, representing a 33% drop. This downtrend is characterized by lower highs and lower lows, with a significant sell-off beginning in late February 2026. In the short term, the stock has underperformed, declining 25.35% over the past three months and 7.42% over the past month. This weakness is more pronounced than the broader market, as indicated by the stock's relative strength of -20.72 and -2.17 against the S&P 500 over the same periods, respectively. The current price of $27.09 sits near the lower end of its 52-week range of $10.44 to $47.65, approximately 42% above the 52-week low. The price experienced a sharp 15.23% single-day rally on March 31, 2026, from $23.51, but this follows a prolonged period of decline.
Beta
0.48
0.48x market volatility
Max Drawdown
-51.7%
Largest decline past year
52-Week Range
$13-$48
Price range past year
Annual Return
+76.6%
Cumulative gain past year
| Period | MLYS Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +4.6% |
| 3m | +1.3% | +8.3% |
| 6m | -32.1% | +12.5% |
| 1y | +76.6% | +25.0% |
| ytd | -20.4% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MLYS Fundamental Analysis
The company is a pre-revenue clinical-stage biotech, with quarterly revenue consistently at $0. It reported a net loss of $32.2 million for Q4 2025, which represents an improvement from a net loss of $48.9 million in Q4 2024. However, profitability metrics like gross margin, operating margin, and net margin are all at 0% or negative, reflecting its development-stage status and lack of product sales. Financially, the company has no debt, as indicated by a debt-to-equity ratio of 0. It maintains a strong current ratio of 43.76, signifying ample short-term liquidity. However, cash flow is negative, with operating cash flow of -$37.9 million and free cash flow of -$37.9 million for the latest quarter, as the company burns cash to fund research and development. Operational efficiency metrics are not applicable in the traditional sense due to the lack of revenue. Return on Equity (ROE) and Return on Assets (ROA) are deeply negative at -23.9% and -24.6%, respectively, which is typical for a company incurring significant R&D expenses without corresponding income.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-142431000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MLYS Overvalued?
Given the company's consistent net losses and negative EBITDA, traditional earnings-based valuation metrics like P/E are not meaningful. The trailing P/E is negative at -15.9, and the forward P/E is also negative at -14.8. Therefore, the valuation must be assessed on a sales basis, but the Price-to-Sales (P/S) ratio is 0 due to zero revenue. The primary valuation metric available is the Price-to-Book (P/B) ratio of 3.80, which values the company's equity at a significant premium to its book value, reflecting investor expectations for its pipeline. Peer comparison data for industry averages is not available in the provided inputs. The valuation is thus largely speculative, based on the potential of its lead drug candidate, lorundrostat, rather than current financial performance.
PE
-15.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -23x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.4x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is clinical and regulatory: the company's entire valuation hinges on the success of its single lead candidate, lorundrostat. Any negative trial results or regulatory setbacks could lead to a severe devaluation. Financial risk is high due to the consistent and substantial cash burn (latest quarterly FCF: -$37.9M) required to fund R&D, though mitigated by a strong, debt-free balance sheet with high liquidity. Market risk is pronounced, as evidenced by the stock's high short interest (ratio: 7.77) and its significant underperformance against the broader market over the past three and six months. As a pre-revenue entity, it lacks the financial stability of commercial-stage companies, making it highly sensitive to sentiment shifts and binary clinical news.
FAQ
The key risks are clinical failure of lorundrostat, which would decimate the stock's value. Financial risks include a high cash burn rate (latest quarterly FCF: -$37.9M). Market risks involve high short interest (ratio: 7.77) and extreme volatility, as shown by its 51.66% max drawdown and significant underperformance versus the S&P 500.
The 12-month outlook is highly bifurcated. The base case (50% probability) sees a range of $25-$35, reflecting ongoing clinical development. The bull case (25%) targets $47+, driven by positive trial data. The bear case (25%) risks a fall to $10-$20 on clinical setbacks. The forecast is entirely dependent on binary clinical events.
MLYS cannot be valued using traditional metrics like P/E (trailing: -15.9) or P/S (0) due to its pre-revenue status. The Price-to-Book ratio of 3.80 suggests the market prices in significant future value from its pipeline. Whether this is over or undervalued is a binary bet on clinical success; there is no fundamental earnings-based anchor.
MLYS is a speculative buy only for investors comfortable with high risk. Its value is based solely on the potential of its lead drug candidate, not current financial performance. The strong balance sheet (no debt, high current ratio) and positive analyst sentiment are positives, but the stock's 33% decline over six months and high short interest signal significant market doubt.
MLYS is strictly a long-term investment for those willing to wait several years for clinical development and potential commercialization. It is unsuitable for short-term trading due to its volatility, event-driven nature, and lack of revenue-based catalysts. The investment thesis requires patience through clinical trial phases and regulatory reviews.
